Drug Profile
Diabetes cell therapy - Diatranz Otsuka Limited
Alternative Names: DiabeCell®; Immunoprotected (alginate-encapsulated) porcine islets - Diatranz Otsuka LimitedLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Living Cell Technologies
- Developer Diatranz Otsuka Limited; Living Cell Technologies; Otsuka Pharmaceutical Factory Inc
- Class Antihyperglycaemics; Cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for clinical-Phase-Unknown development in Type-1 diabetes mellitus in USA (Intraperitoneal, Implant)
- 05 Oct 2017 Discontinued - Registered for Type-1 diabetes mellitus in Russia (Intraperitoneal) before October 2017, because no recent reports on development were identified and Diatranz Otsuka Limited is focussing its efforts on development in USA
- 05 Oct 2017 Diatranz Otsuka Limited plans a phase II/III trial for Type 1 diabetes mellitus in USA (Diatranz Otsuka Limited website, October 2017)